Svb Leerink started coverage on shares of Arrowhead Pharmaceuticals (NASDAQ:ARWR) in a research report report published on Tuesday, BenzingaRatingsTable reports. The brokerage issued an underperform rating and a $32.00 price objective on the biotechnology company’s stock.
ARWR has been the topic of a number of other reports. Robert W. Baird raised Arrowhead Pharmaceuticals from a neutral rating to an outperform rating and upped their price target for the stock from $39.00 to $70.00 in a research note on Monday, November 25th. ValuEngine lowered Arrowhead Pharmaceuticals from a buy rating to a hold rating in a report on Wednesday, October 2nd. Chardan Capital reissued a buy rating and issued a $81.00 price objective (up previously from $45.00) on shares of Arrowhead Pharmaceuticals in a research note on Friday, November 29th. Cantor Fitzgerald restated a neutral rating and set a $50.00 price objective (up previously from $24.00) on shares of Arrowhead Pharmaceuticals in a report on Tuesday, November 19th. Finally, Piper Jaffray Companies boosted their price objective on Arrowhead Pharmaceuticals from $72.00 to $80.00 and gave the company an overweight rating in a report on Monday, December 9th. Two equities research analysts have rated the stock with a sell rating, four have given a hold rating and five have issued a buy rating to the stock. The company presently has an average rating of Hold and a consensus price target of $61.14.
ARWR opened at $47.59 on Tuesday. Arrowhead Pharmaceuticals has a 1-year low of $12.51 and a 1-year high of $73.72. The company has a market cap of $5.40 billion, a P/E ratio of 68.97 and a beta of 1.97. The company has a fifty day moving average price of $62.77 and a two-hundred day moving average price of $42.05.
Arrowhead Pharmaceuticals (NASDAQ:ARWR) last announced its quarterly earnings data on Monday, November 25th. The biotechnology company reported $0.11 earnings per share for the quarter, missing the consensus estimate of $0.14 by ($0.03). The company had revenue of $43.29 million for the quarter, compared to analyst estimates of $36.97 million. Arrowhead Pharmaceuticals had a net margin of 40.27% and a return on equity of 32.30%. As a group, analysts forecast that Arrowhead Pharmaceuticals will post -0.36 earnings per share for the current fiscal year.
In other Arrowhead Pharmaceuticals news, CEO Christopher Richard Anzalone sold 100,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Thursday, December 12th. The shares were sold at an average price of $67.50, for a total transaction of $6,750,000.00. Following the transaction, the chief executive officer now directly owns 2,048,684 shares of the company’s stock, valued at approximately $138,286,170. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is available through this hyperlink. Also, CFO Kenneth Allen Myszkowski sold 20,000 shares of Arrowhead Pharmaceuticals stock in a transaction on Monday, January 6th. The stock was sold at an average price of $60.11, for a total transaction of $1,202,200.00. Following the transaction, the chief financial officer now directly owns 403,592 shares in the company, valued at $24,259,915.12. The disclosure for this sale can be found here. Insiders sold a total of 246,089 shares of company stock worth $15,145,844 in the last 90 days. 4.80% of the stock is currently owned by company insiders.
Several hedge funds and other institutional investors have recently bought and sold shares of the company. Parametric Portfolio Associates LLC lifted its position in shares of Arrowhead Pharmaceuticals by 60.1% during the second quarter. Parametric Portfolio Associates LLC now owns 80,302 shares of the biotechnology company’s stock valued at $2,128,000 after purchasing an additional 30,147 shares in the last quarter. Vanguard Group Inc. boosted its holdings in Arrowhead Pharmaceuticals by 75.4% during the second quarter. Vanguard Group Inc. now owns 8,637,838 shares of the biotechnology company’s stock worth $228,903,000 after purchasing an additional 3,712,392 shares during the last quarter. Man Group plc purchased a new position in Arrowhead Pharmaceuticals during the second quarter worth about $537,000. AQR Capital Management LLC grew its position in Arrowhead Pharmaceuticals by 81.3% in the 2nd quarter. AQR Capital Management LLC now owns 351,710 shares of the biotechnology company’s stock worth $9,320,000 after purchasing an additional 157,759 shares in the last quarter. Finally, Morgan Stanley grew its position in Arrowhead Pharmaceuticals by 93.4% in the 2nd quarter. Morgan Stanley now owns 516,057 shares of the biotechnology company’s stock worth $13,676,000 after purchasing an additional 249,240 shares in the last quarter. Hedge funds and other institutional investors own 70.33% of the company’s stock.
Arrowhead Pharmaceuticals Company Profile
Arrowhead Pharmaceuticals, Inc develops medicines for the treatment of intractable diseases in the United States. The company's pipeline include ARO-AAT, a RNA interference (RNAi) therapeutic candidate for the treatment of liver diseases associated with alpha-1 antitrypsin deficiency; ARO-APOC3 to treat hypertriglyceridemia; ARO-ANG3 to reduce production of angiopoietin-like protein 3; ARO-ENaC to reduce production of the epithelial sodium channel alpha subunit in the airways of the lung; and ARO-HIF2 for the treatment of clear cell renal cell carcinoma.
See Also: What is Cost of Goods Sold (COGS)?
Receive News & Ratings for Arrowhead Pharmaceuticals Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Arrowhead Pharmaceuticals and related companies with MarketBeat.com's FREE daily email newsletter.